Avalo Therapeutics Inc (AVTX NASDAQ) stock market data APIs
$4.7632
0.01(0.2%)
as of April 25, 2025
Avalo Therapeutics Inc Financial Data Overview
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Prev. Close
4.7632
Open
4.7774
High
4.8511
Low
4.6485
52 wk Range
4.15-17.49
Market Cap
52 079 K
Shares Outstanding
10 672 K
Revenue
441 K
EPS
-2.74
Beta
0.724
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avalo Therapeutics Inc data using free add-ons & libraries
Get Avalo Therapeutics Inc Fundamental Data
Avalo Therapeutics Inc Fundamental data includes:
- Net Revenue: 441 K
- EBITDA: -40 702 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-27
- EPS/Forecast: 1.665
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avalo Therapeutics Inc News
New
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysre...
The 3 Best Personalized Nutrition Stocks to Buy Now
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machin...
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo�...
Avalo Completes Divestiture of AVTX-800 Series
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, asset...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
